WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the publication of a review article in the Journal of Vascular Anomalies examining clinical differences and treatment approaches for microcystic and macrocystic lymphatic malformations.
The company said the publication highlights distinctions in genetics, disease progression, and treatment response between the two subtypes, with a focus on guiding clinical trial design and therapeutic strategies.
The review identifies microcystic lymphatic malformations as a condition with no U.S. Food and Drug Administration-approved therapies and describes it as more difficult to treat due to diffuse tissue involvement and frequent recurrence.
Maria Buethe, a pediatric dermatology specialist and senior author of the publication, said the findings reinforce the need for subtype-specific treatment approaches.
“Microcystic lymphatic malformations remain one of the most difficult-to-treat vascular anomalies and represent a substantial unmet medical need,” Buethe said. “These distinctions underscore that lymphatic malformations cannot be approached as a single disease.”
The article also outlines key clinical differences, including cyst size, structure, common locations, and response to treatment, and notes that microcystic forms do not typically resolve without intervention.
Palvella said the publication supports the scientific rationale for its investigational therapy, QTORIN rapamycin gel, which has demonstrated results in a Phase 3 trial.
Jeff Martini, the company’s chief scientific officer, said the findings highlight limitations of current procedural treatments.
“This publication reinforces that current procedural approaches are often inadequate for microcystic disease,” Martini said.
Microcystic lymphatic malformations are described as a rare, progressive condition linked to dysregulation of cellular growth pathways, affecting an estimated more than 30,000 patients in the United States, according to the publication.
Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for rare skin diseases and vascular malformations.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.